UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER
kmUU300MXic
kmUU300MXic
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Presentations<br />
KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab<br />
(ipi) for advanced melanoma: Efficacy by PD-L1 expression and line<br />
of therapy.<br />
Authors*: Adil Daud, Christian U. Blank, Caroline Robert, Igor Puzanov, Erika Richtig, Kim Allyson Margolin,<br />
Steven O’Day, Marta Nyakas, Jose Lutzky, Ahmad A. Tarhini, Elaine McWhirter, Christian Caglevic,<br />
Peter Mohr, Michael Millward, Marcus O. Butler, Honghong Zhou, Kenneth Emancipator, Scot Ebbinghaus,<br />
Nageatte Ibrahim, Georgina V. Long<br />
Abstract #: 9513<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #118<br />
Poster Session: Melanoma/Skin Cancers<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9513)<br />
Daud Research Interests: Our group at <strong>UCSF</strong> is focused on developing new immunotherapy agents and<br />
specifically understanding the biology of the immune response to PD-1 in melanoma. We developed IL-<br />
12 gene therapy in melanoma and carried out the first in human clinical trial in 2005-2007. Based on this<br />
work, IL-12 electroporation is being explored in many cancers as an immune agent and as a combination<br />
treatment with PD-1 and other checkpoint inhibitors in melanoma. I have been involved in the development<br />
of anti-PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and Max Krummel at<br />
<strong>UCSF</strong>, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can<br />
predict non-response to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets<br />
of melanoma (and potentially other cancers).<br />
http://cancer.ucsf.edu/people/profiles/daud_adil.3622<br />
__________________________________________________________________________<br />
Anti-PD-1 therapy in patients with advanced melanoma and preexisting<br />
autoimmune disorders (AD) or major toxicity with ipilimumab (IPI).<br />
Authors*: Alexander M. Menzies, Douglas Buckner Johnson, Sangeetha Ramanujam, Victoria Atkinson,<br />
Annie N.M. Wong, John J Park, Jennifer Leigh McQuade, Alexander Noor Shoushtari, Katy K. Tsai,<br />
Zeynep Eroglu, Oliver Klein, Jessica Cecile Hassel, Jeffrey Alan Sosman, Alex Guminski, Ryan J. Sullivan,<br />
Antoni Ribas, Matteo S. Carlino, Michael A. Davies, Shahneen Kaur Sandhu, Georgina V. Long<br />
Abstract #: 9515<br />
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #120<br />
Session: Melanoma/Skin Cancers<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9515)<br />
*<strong>UCSF</strong> authors in bold<br />
30
Change language